Drug Profile
HT 61/mupirocin/neomycin - Cadila Pharmaceuticals
Alternative Names: HT61/mupirocin/neomycin - Cadila Pharmaceuticals; HY 005; HY-005B8a; HY-005B8a topical; Mupirocin/neomycin/HT-61 - Cadila Pharmaceuticals; Neomycin/HT-61/mupirocin - Cadila PharmaceuticalsLatest Information Update: 12 Dec 2022
Price :
$50
*
At a glance
- Originator Cadila Pharmaceuticals
- Class Aminoglycosides; Antibacterials; Carboxylic acids; Epoxy compounds; Nonanoic acids; Pyrans; Skin disorder therapies; Small molecules
- Mechanism of Action Cell membrane inhibitors; Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 12 Dec 2022 HT 61/mupirocin/neomycin is still in phase II development for Methicillin-resistant Staphylococcus aureus infections at Unknown location (Helperby Therapeutics pipeline, December 2022)
- 15 Jun 2020 Helperby Therapeutics completes a phase II trial in Methicillin-resistant Staphylococcus aureus infections (Topical), before June 2020 (Helperby Therapeutics pipeline, June 2020)
- 04 Jul 2019 Phase-II clinical trials in Methicillin-resistant Staphylococcus aureus infections (Topical) before July 2019 (Helperby Therapeutics pipeline, July 2019)